US Patent 10188644 | Patents | Expiry | Expiration | Dates

COLLEGIUM PHARM INC

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

OXYCODONE

Supporting Information : Click here to upload a PDF

US Patent Number

10188644

Drug Substance Claim

Drug Product Claim

Y

Patent Expiration Date

2036-09-02

Patent Use Code

U-1556

Delist Requested

Application Number

208090

Patent Use Description

MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQ

Product Number

2

COLLEGIUM PHARM INC

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

OXYCODONE

Supporting Information : Click here to upload a PDF

US Patent Number

10188644

Drug Substance Claim

Drug Product Claim

Y

Patent Expiration Date

2036-09-02

Patent Use Code

U-1556

Delist Requested

Application Number

208090

Patent Use Description

MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQ

Product Number

5

COLLEGIUM PHARM INC

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

OXYCODONE

Supporting Information : Click here to upload a PDF

US Patent Number

10188644

Drug Substance Claim

Drug Product Claim

Y

Patent Expiration Date

2036-09-02

Patent Use Code

U-1556

Delist Requested

Application Number

208090

Patent Use Description

MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQ

Product Number

4

COLLEGIUM PHARM INC

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

OXYCODONE

Supporting Information : Click here to upload a PDF

US Patent Number

10188644

Drug Substance Claim

Drug Product Claim

Y

Patent Expiration Date

2036-09-02

Patent Use Code

U-1556

Delist Requested

Application Number

208090

Patent Use Description

MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQ

Product Number

3

COLLEGIUM PHARM INC

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

OXYCODONE

Supporting Information : Click here to upload a PDF

US Patent Number

10188644

Drug Substance Claim

Drug Product Claim

Y

Patent Expiration Date

2036-09-02

Patent Use Code

U-1556

Delist Requested

Application Number

208090

Patent Use Description

MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQ

Product Number

Find

Information, Expiry & Status of FDA Orange Book Patents covering 10188644

COLLEGIUM PHARM INC

Y

2036-09-02

U-1556

MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQ

2

COLLEGIUM PHARM INC

Y

2036-09-02

U-1556

MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQ

5

COLLEGIUM PHARM INC

Y

2036-09-02

U-1556

MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQ

4

COLLEGIUM PHARM INC

Y

2036-09-02

U-1556

MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQ

3

COLLEGIUM PHARM INC

Y

2036-09-02

U-1556

MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQ

1